Abstract:AIM:Point mutation, one of the commonest gene mutations, is the most important molecular pathogenesis of cancer and chronic infection. The commonest methods for detection of point mutation are based on polymerase chain reaction (PCR). These techniques, however, cannot be used in large scale screening since they are neither accurate nor simple. For this reason, this study established a novel method of competitively differentiated PCR (CD-PCR) for screening point mutation in clinical practice.METHODS:Two competitively differentiated primers for mutant-type and wild-type templates respectively with an identically complemented region in 3' end except for last 2 base pairs and a different non-complemented region in 5' end were designed. Thus, competitive amplification might be carried out at a lower annealing temperature at first, and then differentiated amplification at a higher annealing temperature when primers could not combine with initial templates. The amplification was performed in one-tube. The products of CD-PCR were detected using microplate hybridization assay. CD-PCR was evaluated by detecting G1896A variant of hepatitis B virus (HBV) in form of recombinant plasmids and in sera from patients with hepatitis B, and compared with allele-specific PCR (AS-PCR) and competitive AS-PCR.RESULTS:CD-PCR was successfully established. It could clearly distinguish wild-type and mutant-type plasmid DNA of G1896A variant when the amount of plasmid DNA was between 10(2)-10(8)copies/reaction, while for AS-PCR and competitive AS-PCR, the DNA amount was between 10(2)-10(4)copies/reaction. CD-PCR could detect one copy of G1896A variant among 10-100 copies of wild-type plasmid DNA. The specificity of CD-PCR was higher than those of AS-PCR and competitive AS-PCR in the detection of HBV G1896A variant in sera from patients with hepatitis B. CD-PCR was independent of the amount of HBV DNA in serum. HBV G1896A variant was more often found in HBeAg (-) patients with a lower level of detectable viremia than that with a higher level of detectable viremia (P=0.0192).CONCLUSION:CD-PCR is more specific since it is less influenced by the amount of initial templates and the cross amplification between mutant- and wild-type amplified products. It is also simple and time-saving. Thus, CD-PCR might be useful in routine gene typing and point mutation screening. HBV G1896A or other more important mutations have to be routinely detected in patients with a detectable level of viremia after HBeAg/antibody conversion in clinical practice.

A New PCR-based in Vitro Neutralization Assay of Hepatitis B Virus

Robust in vitro assay for analyzing the neutralization activity of serum specimens against hepatitis B virus.

An Optimized High-Throughput Neutralization Assay For Hepatitis E Virus (Hev) Involving Detection Of Secreted Porf2

Efficient Neutralizing Activity of Cocktailed Recombinant Human Antibodies Against Hepatitis a Virus Infection in Vitro and in Vivo

Development and Validation of an Indirect ELISA for Detection of Hepatitis B Virus PreS1 Antibody in Mouse Serum

Neutralization Effects of Antibody Elicited by Chimeric HBV S Antigen Viral-Like Particles Presenting HCV Neutralization Epitopes.

A Particle Gel Assay for Detection of Intracellular Hepatitis B Virus Subviral Particles in Cultured Cells

A Human Monoclonal Antibody Against Small Envelope Protein of Hepatitis B Virus with Potent Neutralization Effect.

Establishment and Primary Application of a Mouse Model with Hepatitis B Virus Replication.

The Establishment of High-throughput Neutralization Titer Evaluation Model for Hepatitis E Virus (HEV)

Toward the development of monoclonal antibody-based assays to probe virion-like epitopes in hepatitis B vaccine antigen.

Evaluation of a Novel Fully Automated Real-Time PCR Assay for Hepatitis B Virus DNA Quantification

Novel Assay of Competitively Differentiated Polymerase Chain Reaction for Screening Point Mutation of Hepatitis B Virus.

Isolation of the neutralization ScFvs Against HBV infection from the Immunized Population.

An HBV-tolerant immunocompetent model that effectively simulates chronic hepatitis B virus infection in mice.

A High-Throughput Neutralizing Assay for Antibodies and Sera Against Hepatitis E Virus

Establishment and application of a novel PCR assay for amplifying the full-length reverse transcriptase gene region of genotypes A～D of hepatitis B virus

Establishment of Mice Model with Human Viral Hepatitis B

Establishment of a highly sensitive chemiluminescent detection system for analysis of hepatitis B virus transcription and replication level in vitro

Screening and Evaluation of Novel Compounds against Hepatitis B Virus Polymerase Using Highly Purified Reverse Transcriptase Domain

Preparation and functional evaluation of monoclonal antibodies targeting Hepatitis B Virus Polymerase